23rd Orphan Drugs and Rare Diseases Global Congress 2025 Europe

Addressing the challenges in drug development, treatment availability, and access.

Copthorne Tara Hotel London Kensington, London, UK, London, United Kingdom

Wednesday 19th - Thursday 20th 2025

Bionical Emas is a global Contract Research Organization (CRO) combining Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) to bring life-changing medicines to patients around the world. Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and evidence generation at every stage of the drug development pathway. Early Access Programs (often called Expanded Access, Pre-approval Access, Compassionate Use, Named Patient or Managed Access Programs) deliver potentially life-saving treatments to patients around the world while adding true value to clients through a range of additional cutting-edge services. Bionical Emas are the only specialist Early Access Program (EAP) partner to harness the full power of an established and successful Contract Research Organization. Their global EAP experience in oncology and rare disease is perfectly complemented by a range of in-house services. www.bionicalemas.com

Gold Sponsor

Pulse Infoframe is a pioneer and leading provider in the life science industry with a real-world evidence (“RWE”) generation platform enabling acceleration of scientific research and the development of new therapeutic products. Pulse is impact-focused on ensuring that fit for purpose critical knowledge and insights enable every phase of the drug development process for (i) oncology including skin cancers, Melanoma, Lung, and Ocular Melanoma and Castleman Disease; (ii) ultra-rare and rare diseases such as Lysosomal Storage Diseases, CDKL5-deficiency Disorder, ( iii) PBC and pruritis, (iv) Alport Syndrome, and (v) Narcolepsy. Pulse’s enterprise-grade platform adaptive technology is trusted by a global, ‘blue-chip’ customer base of top pharma companies, patient advocacy groups and academic medical centres.

Associate Sponsor

The 23rd Orphan Drugs & Rare Diseases Global Congress 2025 Europe will be co-located with The 8th Expanded Access Programmes World Congress 2025 Europe,

Shared Exhibit & Networking Area.

Sponsors & Exhibitors will have the benefit of showcasing their Company’s expertise and solutions to attendees from both Events.